Loading data for SLDB — first visit, this takes a few seconds.

Alert

Solid Biosciences Inc. (SLDB)

NasdaqGS: SLDB · Real-Time Price · USD

9.70

+0.62 (6.83%)

At close: Aug 18, 2026, 3:59 PM

6.83% (1D)

Bid	7.03
Market Cap	1.03B
Revenue (ttm)	n/a
Net Income (ttm)	-207.1M
Beta	2.42
EPS (ttm)	-1.89
PE Ratio (ttm)	n/a
Forward PE	-5.48
P/B (ttm)	2.69
P/S (ttm)	n/a
Earnings Date	Nov 2, 2026

Ask	12.01
Volume	264,557
Avg. Volume (20D)	1,613,285
Open	9.42
Previous Close	9.08
Day's Range	9.29 - 9.87
52-Week Range	3.79 - 11.45
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About SLDB

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the trea...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jan 26, 2018

Employees 121

Stock Exchange NasdaqGS

Ticker Symbol SLDB

Website https://www.solidbio.com

Full Company Profile

Financial Performance

In 2025, Solid Biosciences's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -174.32M, an increase of 39.8%.

Financial Statements

Earnings Surprise

Solid Biosciences has released their quarterly earnings on Aug 6, 2026:

Revenue of $0 misses estimates by $0, with NaN% YoY growth.

EPS of -0.38 exceeds estimates by 0.09, with 35.59% YoY growth.

Next Earnings Release

Solid Biosciences Inc. is scheduled to release its earnings on Nov 2, 2026, during market hours.
Analysts project revenue of ... Upgrade

News

1 month ago · Simply Wall St.

Does Solid Biosciences' (SLDB) Russell Growth Index Debut Reveal a Shift in Its Investor Base?

In late June 2026, Solid Biosciences Inc. was added to several Russell growth indexes, including the Russell 3000 Growth, 2000 Growth, 2500 Growth, and Microcap Growth benchmarks. This broad index inc...

2 months ago · MT Newswires

Sarepta's Elevidys Showing Signs of Stabilization as siRNA Pipeline Gains Importance, RBC Says

Sarepta Therapeutics' (SRPT) Elevidys for Duchenne muscular dystrophy shows near-term stabilization,

3 months ago · Insider Monkey

Where Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months?

Solid Biosciences Inc (NASDAQ:SLDB) is one of the best gene therapy stocks to buy in 2026. The stock has been a big win for investors, having gained roughly 75% over the past six months and surged mor...

5 months ago · TipRanks

Solid Biosciences says interim results reinforce confidence in SGT-003 potential

Solid Biosciences (SLDB) reported updated “positive” interim data from the ongoing Phase 1/2 INSPIRE DUCHENNE clinical trial of SGT-003. The new data, including additional muscle biopsy, serum biomark...

5 months ago · Motley Fool

Stock Market Today, March 11: Oracle Surges as Markets Weigh Geopolitical Risks

Today, March 11, 2026, Oracle’s earnings beat and solid inflation data stand out as U.S. stocks wobble on oil and war fears.

Page 1 of 2

Solid Biosciences Inc. (SLDB)